Looking at Rs 100 cr revenues in next 5 years from new OTC segment, says Shilpa Medicare

Shilpa Medicare is in focus as Barings Private Equity sold 7.36 percent stake in the company. Sundeip Bhatia, business head India, Shilpa Medicare discussed this and the outlook of the going forward.

“We are focusing a lot on the expansion part. So basically the main focus is how to go for the expansion in India market and capitalise on the quality we have been building over a period of years by having a unique export potential which we have been doing in the past,” he said.

In terms of the oncology segment, he mentioned, “We are strengthening our business on the oncology segment.”

“We would be entering into the wellness segment. We would be introducing products. We have started with the first product called Green Tea Films, this is a research work of the last four years of our efforts and we are the first company in the world to introduce the film technology and through that, we are entering into the niche mass OTC segment which is Green Tea. We are looking at Rs 100 crore revenues for the first five years. We would be starting the first year anywhere between Rs 15 crore and Rs 20 crore and we would look forward to make it Rs 100 crore brand in five years’ time,” Bhatia further added.